World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
59200
World Ranking
9848
National Ranking
5063

Overview

Pinuccia Valagussa is affiliated with the University of Louisville in the United States. Their research encompasses a broad spectrum of topics primarily within medicine, with specific focus on oncology and cancer-related studies. Over their career, they have contributed to the advancement of knowledge in several interconnected fields including biochemistry, genetics, molecular biology, pulmonary and respiratory medicine, and cancer research.

The scientist's work is concentrated in the study of cancer immunotherapy and biomarkers, HER2/EGFR in cancer research, and breast cancer treatment studies. Additional topics of research cover cancer genomics and diagnostics, advanced breast cancer therapies, monoclonal and polyclonal antibodies research, as well as cancer treatment and pharmacology.

Valagussa's publication record includes frequent contributions to respected journals and venues such as:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Zenodo (CERN European Organization for Nuclear Research)
  • The Lancet Oncology

They have co-authored several papers with notable frequent collaborators including Luca Gianni, Giampaolo Bianchini, Giuseppe Viale, Lucia Del Mastro, and Marc Thill.

Some of their recent publications include the following papers:

  • "Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study", published in 2022 in Annals of Oncology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials", published in 2021 in The Lancet Oncology
  • "Spatial predictors of immunotherapy response in triple-negative breast cancer", published in 2023 in Nature
  • "Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study", published in 2020 in Cancer Research
  • "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials", published in 2023 in The Lancet

Their scholarly contributions have addressed multiple aspects of breast cancer therapies, treatment efficacy, and immunotherapy response predictors, reflecting a consistent thematic engagement with oncology-focused research.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Laslo Roman

  • Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

    Bonadonna G;Brusamolino E;Valagussa P;Rossi A

  • Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

    Luca Gianni;Wolfgang Eiermann;Vladimir Semiglazov;Alexey Manikhas

  • Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

    Gianni Bonadonna;Pinuccia Valagussa;Angela Moliterni;Milvia Zambetti

  • Dose-response effect of adjuvant chemotherapy in breast cancer.

    Gianni Bonadonna;Pinuccia Valagussa

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

  • Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More

    Gianni Bonadonna;Umberto Veronesi;Cristina Brambilla;Laura Ferrari

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Ling Ming Tseng

  • Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

    Gianni Bonadonna;Pinuccia Valagussa;Cristina Brambilla;Laura Ferrari

  • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

    Luca Gianni;Milvia Zambetti;Kim Clark;Joffre Baker

  • High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

    Gianni Am;Bregni M;Siena S;Brambilla C

  • Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients.

    Pinuccia Valagussa;Gianni Bonadonna;Umberto Veronesi

  • Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    Luca Gianni;Wolfgang Eiermann;Vladimir Semiglazov;Ana Lluch

  • Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

    Gianni Bonadonna;Milvia Zambetti;Pinuccia Valagussa

  • ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

    Simonetta Viviani;Pier Luigi Zinzani;Alessandro Rambaldi;Ercole Brusamolino

  • Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's Disease: A Report of 8-Year Results

    Gianni Bonadonna;Pinuccia Valagussa;Armando Santoro

Frequent Co-Authors

Luca Gianni
Luca Gianni Vita-Salute San Raffaele University
Armando Santoro
Armando Santoro Humanitas University
Ana Lluch
Ana Lluch University of Valencia
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Umberto Veronesi
Umberto Veronesi European Institute of Oncology
Giuseppe Viale
Giuseppe Viale University of Milan
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Richard Gray
Richard Gray University of Oxford
Maria Grazia Daidone
Maria Grazia Daidone University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine or healthcare doesn’t always mean following a traditional path. Many students are now pursuing flexible programs to advance their skills and expertise. For those interested in food science and wellness, online nutrition degrees offer a specialized foundation in nutritional care—a growing area within healthcare.

Aspiring healthcare leaders can consider the best mha programs online, which focus on healthcare management and administration for broader career opportunities. Registered nurses (RN) seeking career growth may benefit from rn to bsn online no clinicals programs, which provide a convenient option to earn a bachelor’s degree without in-person clinicals.

For nurses aiming for the highest level of practice, fastest dnp online program options offer an accelerated route to a Doctor of Nursing Practice degree. These pathways are expanding access to advanced healthcare roles and responding to the demands of an evolving medical landscape.

Best Scientists Citing Pinuccia Valagussa

Trending Scientists

Recently Published Articles